These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 22388550)

  • 1. Mammalian target of rapamycin signaling in the podocyte.
    Inoki K; Huber TB
    Curr Opin Nephrol Hypertens; 2012 May; 21(3):251-7. PubMed ID: 22388550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression.
    Huber TB; Walz G; Kuehn EW
    Kidney Int; 2011 Mar; 79(5):502-11. PubMed ID: 21085109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of TSC-mTOR signaling on immune cells in immunity and autoimmunity.
    Yang H; Wang X; Zhang Y; Liu H; Liao J; Shao K; Chu Y; Liu G
    J Cell Physiol; 2014 Jan; 229(1):17-26. PubMed ID: 23804073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GSK3β inactivation in podocytes results in decreased phosphorylation of p70S6K accompanied by cytoskeletal rearrangements and inhibited motility.
    George B; Vollenbröker B; Saleem MA; Huber TB; Pavenstädt H; Weide T
    Am J Physiol Renal Physiol; 2011 May; 300(5):F1152-62. PubMed ID: 21228102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes.
    Vollenbröker B; George B; Wolfgart M; Saleem MA; Pavenstädt H; Weide T
    Am J Physiol Renal Physiol; 2009 Feb; 296(2):F418-26. PubMed ID: 19019920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MTOR regulates autophagic flux in the glomerulus.
    Cinà DP; Onay T; Paltoo A; Li C; Maezawa Y; De Arteaga J; Jurisicova A; Quaggin SE
    Autophagy; 2012 Apr; 8(4):696-8. PubMed ID: 22441016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of TSC-mTOR pathway in diabetic nephropathy.
    Inoki K
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S59-62. PubMed ID: 18926585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice.
    Inoki K; Mori H; Wang J; Suzuki T; Hong S; Yoshida S; Blattner SM; Ikenoue T; Rüegg MA; Hall MN; Kwiatkowski DJ; Rastaldi MP; Huber TB; Kretzler M; Holzman LB; Wiggins RC; Guan KL
    J Clin Invest; 2011 Jun; 121(6):2181-96. PubMed ID: 21606597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state kinetic and inhibition studies of the mammalian target of rapamycin (mTOR) kinase domain and mTOR complexes.
    Tao Z; Barker J; Shi SD; Gehring M; Sun S
    Biochemistry; 2010 Oct; 49(39):8488-98. PubMed ID: 20804212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice.
    Gödel M; Hartleben B; Herbach N; Liu S; Zschiedrich S; Lu S; Debreczeni-Mór A; Lindenmeyer MT; Rastaldi MP; Hartleben G; Wiech T; Fornoni A; Nelson RG; Kretzler M; Wanke R; Pavenstädt H; Kerjaschki D; Cohen CD; Hall MN; Rüegg MA; Inoki K; Walz G; Huber TB
    J Clin Invest; 2011 Jun; 121(6):2197-209. PubMed ID: 21606591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR-mediated podocyte hypertrophy regulates glomerular integrity in mice and humans.
    Puelles VG; van der Wolde JW; Wanner N; Scheppach MW; Cullen-McEwen LA; Bork T; Lindenmeyer MT; Gernhold L; Wong MN; Braun F; Cohen CD; Kett MM; Kuppe C; Kramann R; Saritas T; van Roeyen CR; Moeller MJ; Tribolet L; Rebello R; Sun YB; Li J; Müller-Newen G; Hughson MD; Hoy WE; Person F; Wiech T; Ricardo SD; Kerr PG; Denton KM; Furic L; Huber TB; Nikolic-Paterson DJ; Bertram JF
    JCI Insight; 2019 Sep; 4(18):. PubMed ID: 31534053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR signaling pathway and mTOR inhibitors in cancer therapy.
    Gomez-Pinillos A; Ferrari AC
    Hematol Oncol Clin North Am; 2012 Jun; 26(3):483-505, vii. PubMed ID: 22520976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin and the kidney. I. The signaling pathway.
    Lieberthal W; Levine JS
    Am J Physiol Renal Physiol; 2012 Jul; 303(1):F1-10. PubMed ID: 22419691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting signaling pathways in glomerular diseases.
    Henique C; Tharaux PL
    Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):417-27. PubMed ID: 22660552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring mammalian target of rapamycin (mTOR) activity.
    Ikenoue T; Hong S; Inoki K
    Methods Enzymol; 2009; 452():165-80. PubMed ID: 19200882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current state of mTOR targeting in human breast cancer.
    Wazir U; Wazir A; Khanzada ZS; Jiang WG; Sharma AK; Mokbel K
    Cancer Genomics Proteomics; 2014; 11(4):167-74. PubMed ID: 25048346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolutionarily conserved regulation of TOR signalling.
    Takahara T; Maeda T
    J Biochem; 2013 Jul; 154(1):1-10. PubMed ID: 23698095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian target of rapamycin complex 1 activation in podocytes promotes cellular crescent formation.
    Mao J; Zeng Z; Xu Z; Li J; Jiang L; Fang Y; Xu X; Hu Z; He W; Yang J; Dai C
    Am J Physiol Renal Physiol; 2014 Nov; 307(9):F1023-32. PubMed ID: 24990893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [TOR-centric concept of regulation mitogenic, metabolic and energetic signal processing in cell].
    Zubova SG; Shitikova ZhV; Pospelova TV
    Tsitologiia; 2012; 54(8):589-602. PubMed ID: 23074850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of mechanistic target of rapamycin in maintenance of glomerular epithelial cells.
    Yao Y; Inoki K
    Curr Opin Nephrol Hypertens; 2016 Jan; 25(1):28-34. PubMed ID: 26625863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.